Biotronik announced today that it won CE Mark approval in the European Union for its PK Papyrus coronary stent system.
The Papyrus device is approved for treating acute coronary artery perforation, and features an innovative “electrospun” membrane to increase flexibility by 58% over its competitors, according to a Biotronik company statement.
"PK Papyrus is a testament to the engineering excellence at Biotronik," Biotronik vascular intervention marketing vice president Dr. Alexander Uhl said in prepared remarks. "The application of this electrospinning technology to the already highly deliverable Biotronik Orsiro/PRO-Kinetic Energy stent platform has allowed us to introduce a novel product to the market that will enable physicians to treat patients in emergency situations quickly and safely."
This is another win for the Berlin-based company, which last month launched its Ilesto cardiac implants, after receiving FDA approval in May. The implants allow for remote monitoring by physicians, in addition to being thinner and smaller than others, according to Biotronik.